SBFM
Sunshine Biopharma Inc.
stock NASDAQ

Sunshine BioPharma (NASDAQ: SBFM) is expected to release its earnings report between November 4th and 16th, with most analysts anticipating the announcement on November 11th.
**Why consider investing in Sunshine BioPharma?**
SBFM is a Canadian pharmaceutical company focused on manufacturing and distributing generic medications within Canada—eliminating concerns about international tariffs. The company has recently expanded its product line with several key launches:
* **Domperidone** – an anti-nausea medication used to treat chemotherapy-induced nausea and vomiting.
* **Doxycycline** – an antibiotic used for treating STIs such as syphilis, as well as acne and Lyme disease.
* **Pravastatin** – an anti-cholesterol medication that helps manage high cholesterol levels.
* **Niopeg** – designed to reduce the risk of infection in patients with non-myeloid cancers receiving chemotherapy.
In total, SBFM now boasts **72 generic medications** in its product portfolio and continues to expand with new formulations in development. Beyond its generics business, the company is also advancing innovative research—including **K1.1 mRNA**, an mRNA–lipid nanoparticle therapy targeting liver cancer, and a treatment candidate for **SARS coronavirus infections**.
Currently, SBFM shares trade around **$1.78**, with **Aegis Capital rating the stock a “BUY”** and setting a **target price of $7.00**, implying potential upside of more than **300%**.
While some short sellers have attempted to pressure the stock, Sunshine BioPharma’s strong fundamentals, expanding product line, and promising R&D pipeline position it for significant long-term growth. This is a call to all investors—short-term traders, swing traders, and long-term holders alike—to recognize the company’s potential and help drive SBFM toward its true valuation.
*Stay tuned for the upcoming earnings report—it could be a pivotal moment for Sunshine BioPharma.*

Sunshine BioPharma (NASDAQ: SBFM) is expected to release its earnings report between November 4th and 16th, with most analysts anticipating the announcement on November 11th.
**Why consider investing in Sunshine BioPharma?**
SBFM is a Canadian pharmaceutical company focused on manufacturing and distributing generic medications within Canada—eliminating concerns about international tariffs. The company has recently expanded its product line with several key launches:
* **Domperidone** – an anti-nausea medication used to treat chemotherapy-induced nausea and vomiting.
* **Doxycycline** – an antibiotic used for treating STIs such as syphilis, as well as acne and Lyme disease.
* **Pravastatin** – an anti-cholesterol medication that helps manage high cholesterol levels.
* **Niopeg** – designed to reduce the risk of infection in patients with non-myeloid cancers receiving chemotherapy.
In total, SBFM now boasts **72 generic medications** in its product portfolio and continues to expand with new formulations in development. Beyond its generics business, the company is also advancing innovative research—including **K1.1 mRNA**, an mRNA–lipid nanoparticle therapy targeting liver cancer, and a treatment candidate for **SARS coronavirus infections**.
Currently, SBFM shares trade around **$1.78**, with **Aegis Capital rating the stock a “BUY”** and setting a **target price of $7.00**, implying potential upside of more than **300%**.
While some short sellers have attempted to pressure the stock, Sunshine BioPharma’s strong fundamentals, expanding product line, and promising R&D pipeline position it for significant long-term growth. This is a call to all investors—short-term traders, swing traders, and long-term holders alike—to recognize the company’s potential and help drive SBFM toward its true valuation.
*Stay tuned for the upcoming earnings report—it could be a pivotal moment for Sunshine BioPharma.*